Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience.

Turk J Ophthalmol · 2023 · PMC9973208 · PMID 36847631

Europe PMC DOI

hedged sentence

0.3210

closest p · 6.4× alpha

0.3210

boldest claim

The sentences

did not reach statistical significancep=0.321not close (p > 0.1)

Although the mean improvement in BCVA at month 12 was higher with aflibercept monotherapy (+6.5 ETDRS letters; 95% CI: 4.1-7.6) than with ranibizumab monotherapy (+5.7 ETDRS letters; 95% CI: 3.4-6.8), this did not reach statistical significance (p=0.321).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.